CKD Bio (063160) Fundamentals 2026 — Revenue Analysis | SniperIQ
CKD Bio (063160) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩70.3B, trading at ₩12820.00 on the KSC. This SniperIQ fundamentals page covers CKD Bio's valuation, profitability (net margin -3.7%), revenue (₩160.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CKD Bio's market cap?
CKD Bio (063160) has a market capitalization of approximately ₩70.3B, trading at ₩12820.00 on the KSC. Market cap moves with the live share price.
What is CKD Bio's P/E ratio?
CKD Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CKD Bio?
CKD Bio runs a net profit margin of -3.7%, a gross margin of 13.9%, and an operating margin of -0.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CKD Bio generate?
CKD Bio reported revenue of ₩160.1B for fiscal year 2025, with net income of -₩2.9B and earnings per share (EPS) of -526.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CKD Bio pay a dividend?
CKD Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CKD Bio financially healthy?
CKD Bio carries a debt-to-equity ratio of 1.18x and a current ratio of 1.10x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CKD Bio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CKD Bio (063160) the key facts are: market cap ₩70.3B, revenue ₩160.1B, 52-week range 12150-27650. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CKD Bio's full fundamentals live
Get CKD Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.